The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - MTrap; Nasasbiotech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen; Lilly; MSD; Roche
Speakers' Bureau - Lilly; Novartis; Pfizer; Roche
Research Funding - Lilly (Inst); Merck (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer; Pierre Fabre; Roche; Tesaro
 
Consulting or Advisory Role - Celgene; Pfizer
Research Funding - Celgene (Inst); Pfizer (Inst)
Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
 
Michele Reni
Consulting or Advisory Role - AstraZeneca; Baxalta/Shire; Baxter; Celgene; Lilly; Sanofi
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene
Other Relationship - AstraZeneca; Celgene
 
Hanno Riess
Consulting or Advisory Role - Aspen Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Pfizer
Research Funding - Bayer (Inst); Leo Pharma (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)
 
Joon Oh Park
Consulting or Advisory Role - AstraZeneca; Celgene; Merck Serono; Sanofi; SERVIER; Shire
Speakers' Bureau - Celgene
Research Funding - Celgene
 
Hassan Hatoum
Consulting or Advisory Role - Foundation Medicine
 
Berta Laquente Saez
No Relationships to Disclose
 
Tapio Salminen
Research Funding - Amgen; Lilly; Merck; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Celgene; Merck
 
Helmut Oettle
No Relationships to Disclose
 
Rafael Lopez
No Relationships to Disclose
 
Scot D. Dowden
Consulting or Advisory Role - Amgen; Celgene; Roche; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Celgene; Roche; Taiho Pharmaceutical
 
Meinolf Karthaus
Expert Testimony - BMS Brazil; Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Inst); Celgene (Inst)
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Ipsen; Merck; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Ipsen
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
David Goldstein
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Bayer Health; Celgene; Clovis Oncology; Cornerstone Pharmaceuticals; Eisai; EMD Serono; Five Prime Therapeutics; Genentech/Roche; ipsen; lsk biopharma; qed therapeutics; Seagen
Research Funding - Bayer (Inst); BeiGene (Inst); boston biomedical (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); pfizer (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; Bayer; boston Biomedical; EMD Serono; Seagen
Other Relationship - AstraZeneca
 
Margaret A. Tempero
Honoraria - Japan Pancreas Society; Oregon Health & Science University (OHSU)
Consulting or Advisory Role - Abbvie; Advance Medical; Astellas Pharma; AstraZeneca; BIOPHARM; Bristol-Myers Squibb; Celgene (Inst); CPRIT; EcoR1 Capital; Eisai; FibroGen (Inst); Halozyme (Inst); Ignyta; Immunovia; Merck; Pharmacyclics; Pharmacyte Biotech; Tocagen
Research Funding - Celgene (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; BIOPHARM; Bristol-Myers Squibb; Celgene; CPRIT; Eisai; Halozyme; Pharmacyclics; Pharmacyte Biotech; Tocagen